HC Wainwright Raises Cardiff Oncology (NASDAQ:CRDF) Price Target to $14.00

Cardiff Oncology (NASDAQ:CRDF – Free Report) had its target price hoisted by HC Wainwright from $12.00 to $14.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Cardiff Oncology’s Q1 2024 earnings at ($0.23) EPS, Q2 2024 earnings at […]

Related Keywords

California ,United States ,Piper Sandler ,Renaissance Technologies ,Cardiff Oncology Inc ,Securities Exchange Commission ,Citigroup Inc ,Walleye Capital ,Vanguard Group Inc ,Cardiff Oncology ,Free Report ,Director Gary ,Exchange Commission ,Gate Manager ,Get Free Report ,Polo Like Kinase ,Cardiff Oncology Daily ,